Allergen biodistribution in humans

Marcello Bagnascoa, Silvia Morbelli, Vania Altrinetti, Paolo Falagiani, Giuliano Mariani, Giovanni Passalacqua

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Specific immunotherapy performed by noninjectable (oral, nasal or oromucosal) routes was mostly developed in the last 20 years with the main aim to avoid side effects that occasionally occur in the course of injectable immunotherapy. Although evidence of its clinical efficacy has been provided some pharmacokinetics aspects are still to be elucidated. In this review we discuss experimental findings of mucosal processing, biodistribution in healthy or allergic humans of 123I-labelled major allergen of Parietariajudaica (the most important cause of seasonal allergy in the Mediterranean area) administered by sublingual or nasal routes. The results available to date show that most allergen administered by mucosal route is absorbed via the gastrointestinal tract; however, a proportion is retained at the mucosal level for a relatively long time. These data are potentially useful to improve immunotherapy treatment protocols by noninjectable routes.

Original languageEnglish
Pages (from-to)33-43
Number of pages11
JournalChemical Immunology and Allergy
Volume82
Publication statusPublished - 2003

Fingerprint

Immunotherapy
Allergens
Nose
Clinical Protocols
Gastrointestinal Tract
Hypersensitivity
Pharmacokinetics
Injections

Keywords

  • Immunotherapy
  • Local immunotherapy
  • Non injective administration
  • Parietaria judaica
  • Radiolabelled allergen

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Bagnascoa, M., Morbelli, S., Altrinetti, V., Falagiani, P., Mariani, G., & Passalacqua, G. (2003). Allergen biodistribution in humans. Chemical Immunology and Allergy, 82, 33-43.

Allergen biodistribution in humans. / Bagnascoa, Marcello; Morbelli, Silvia; Altrinetti, Vania; Falagiani, Paolo; Mariani, Giuliano; Passalacqua, Giovanni.

In: Chemical Immunology and Allergy, Vol. 82, 2003, p. 33-43.

Research output: Contribution to journalArticle

Bagnascoa, M, Morbelli, S, Altrinetti, V, Falagiani, P, Mariani, G & Passalacqua, G 2003, 'Allergen biodistribution in humans', Chemical Immunology and Allergy, vol. 82, pp. 33-43.
Bagnascoa M, Morbelli S, Altrinetti V, Falagiani P, Mariani G, Passalacqua G. Allergen biodistribution in humans. Chemical Immunology and Allergy. 2003;82:33-43.
Bagnascoa, Marcello ; Morbelli, Silvia ; Altrinetti, Vania ; Falagiani, Paolo ; Mariani, Giuliano ; Passalacqua, Giovanni. / Allergen biodistribution in humans. In: Chemical Immunology and Allergy. 2003 ; Vol. 82. pp. 33-43.
@article{a8a80e959704401ab9aebbdf43c1104f,
title = "Allergen biodistribution in humans",
abstract = "Specific immunotherapy performed by noninjectable (oral, nasal or oromucosal) routes was mostly developed in the last 20 years with the main aim to avoid side effects that occasionally occur in the course of injectable immunotherapy. Although evidence of its clinical efficacy has been provided some pharmacokinetics aspects are still to be elucidated. In this review we discuss experimental findings of mucosal processing, biodistribution in healthy or allergic humans of 123I-labelled major allergen of Parietariajudaica (the most important cause of seasonal allergy in the Mediterranean area) administered by sublingual or nasal routes. The results available to date show that most allergen administered by mucosal route is absorbed via the gastrointestinal tract; however, a proportion is retained at the mucosal level for a relatively long time. These data are potentially useful to improve immunotherapy treatment protocols by noninjectable routes.",
keywords = "Immunotherapy, Local immunotherapy, Non injective administration, Parietaria judaica, Radiolabelled allergen",
author = "Marcello Bagnascoa and Silvia Morbelli and Vania Altrinetti and Paolo Falagiani and Giuliano Mariani and Giovanni Passalacqua",
year = "2003",
language = "English",
volume = "82",
pages = "33--43",
journal = "Progress in Allergy",
issn = "1660-2242",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Allergen biodistribution in humans

AU - Bagnascoa, Marcello

AU - Morbelli, Silvia

AU - Altrinetti, Vania

AU - Falagiani, Paolo

AU - Mariani, Giuliano

AU - Passalacqua, Giovanni

PY - 2003

Y1 - 2003

N2 - Specific immunotherapy performed by noninjectable (oral, nasal or oromucosal) routes was mostly developed in the last 20 years with the main aim to avoid side effects that occasionally occur in the course of injectable immunotherapy. Although evidence of its clinical efficacy has been provided some pharmacokinetics aspects are still to be elucidated. In this review we discuss experimental findings of mucosal processing, biodistribution in healthy or allergic humans of 123I-labelled major allergen of Parietariajudaica (the most important cause of seasonal allergy in the Mediterranean area) administered by sublingual or nasal routes. The results available to date show that most allergen administered by mucosal route is absorbed via the gastrointestinal tract; however, a proportion is retained at the mucosal level for a relatively long time. These data are potentially useful to improve immunotherapy treatment protocols by noninjectable routes.

AB - Specific immunotherapy performed by noninjectable (oral, nasal or oromucosal) routes was mostly developed in the last 20 years with the main aim to avoid side effects that occasionally occur in the course of injectable immunotherapy. Although evidence of its clinical efficacy has been provided some pharmacokinetics aspects are still to be elucidated. In this review we discuss experimental findings of mucosal processing, biodistribution in healthy or allergic humans of 123I-labelled major allergen of Parietariajudaica (the most important cause of seasonal allergy in the Mediterranean area) administered by sublingual or nasal routes. The results available to date show that most allergen administered by mucosal route is absorbed via the gastrointestinal tract; however, a proportion is retained at the mucosal level for a relatively long time. These data are potentially useful to improve immunotherapy treatment protocols by noninjectable routes.

KW - Immunotherapy

KW - Local immunotherapy

KW - Non injective administration

KW - Parietaria judaica

KW - Radiolabelled allergen

UR - http://www.scopus.com/inward/record.url?scp=0347022417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347022417&partnerID=8YFLogxK

M3 - Article

C2 - 12947990

AN - SCOPUS:0347022417

VL - 82

SP - 33

EP - 43

JO - Progress in Allergy

JF - Progress in Allergy

SN - 1660-2242

ER -